Golden Pharmaceutical Industries Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.65 M
- Company Age 44 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.18 M
- Revenue Growth %
- Profit Growth -55.84%
- Ebitda -303.00%
- Net Worth -2.13%
- Total Assets -63.07%
About Golden Pharmaceutical Industries
Golden Pharmaceutical Industries Private Limited (GPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 May 1980 and has a history of 44 years and eight months. Its registered office is in Jammu, Jammu & Kashmir, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.65 M.
The company currently has active open charges totaling ₹0.18 M.
Parveen Jain and Naveen Jain serve as directors at the Company.
Company Details
-
Location
Jammu, Jammu & Kashmir, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231JK1980PTC000458
-
Company No.
000458
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 May 1980
-
Date of AGM
28 Aug 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Jammu
Industry
Who are the key members and board of directors at Golden Pharmaceutical Industries?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parveen Jain
|
Director | 27-Mar-2023 | Current |
|
Naveen Jain
|
Director | 27-Mar-2023 | Current |
Financial Performance of Golden Pharmaceutical Industries.
Golden Pharmaceutical Industries Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 55.84% decrease in profit. The company's net worth dipped by a decrease of 2.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Golden Pharmaceutical Industries?
In 2023, Golden Pharmaceutical Industries had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.18 M
₹0
Charges Breakdown by Lending Institutions
- `Bank Of Baroda : 0.01 Cr
- Bank Of Baroda : 0.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Feb 1981 | `Bank Of Baroda | ₹0.10 M | Open |
| 07 Oct 1980 | Bank Of Baroda | ₹0.08 M | Open |
How Many Employees Work at Golden Pharmaceutical Industries?
Unlock and access historical data on people associated with Golden Pharmaceutical Industries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Golden Pharmaceutical Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Golden Pharmaceutical Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
